Piramal Pharma Ltd.
NSE: PPLPHARMAPiramal Pharma Ltd.: A 30-second snapshot
Piramal Pharma (PPLPHARMA) is a pharma CDMO and consumer health business trading at ₹174.87, down 18.55% over 12 months and 22.57% from its 52-week high. The company is currently loss-making with trailing ROE of -4% and net margin of -3.67%, while carrying a debt-to-equity ratio of 69.52. A 6.39% price recovery over the past 3 months has lifted the stock above its 50-DMA (₹153.42) but it remains below its 200-DMA (₹176.22).
P/E
—
Forward P/E
40.4
ROE
-4.0%
Debt / Equity
69.52
Profit Margin
-3.7%
Div. Yield
+0.1%
5Y ROE > 15%
0/5
5Y FCF > 0
3/5
Quality
39/100
News
8 headlines · 4 positive · 0 negative
Piramal Pharma Limited Announces Results for Q4 and Full-year FY26 - TheWire.in
TheWire.in
India's Piramal Pharma eyes complex drug demand for earnings boost, chair says - TradingView
TradingView
India's Piramal Pharma eyes complex drug demand for earnings boost, chair says - marketscreener.com
marketscreener.com
PPLPHARMA: FY26 ended with stable revenue and improved outlook, setting up for growth in FY27 - TradingView
TradingView
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility - Business Standard
Business Standard
Recent context
- ·Q4 and full-year FY26 results were reported in late April 2026; management flagged complex drug demand — including the new payload-linker suite at the Michigan facility — as a growth lever for FY27.
- ·The stock has gained 6.39% over 3 months, moving above the 50-DMA (₹153.42) from support levels; the nearest resistance levels in the technical dataset are ₹185.04 and ₹196.44.
- ·Despite positive recent news sentiment and the short-term price recovery, the trailing 12-month return stands at -18.55%, and the company carries no analyst consensus mean rating in the current dataset (11 analysts tracked).
Strengths
- +FCF was positive in 3 of available fiscal years, suggesting the business can generate cash at the operating level even during loss-reporting periods.
- +Quality score of 31 ranks 4th of 6 sector peers in the dataset, ahead of Cipla (24) and Dr. Reddy's (17) on this specific composite metric.
- +RSI of 61.08 is in neutral territory, and the stock has recovered 6.39% over 3 months from support near ₹148–₹132 levels identified in technical data.
- +News flow over the review period showed 4 positive and 0 negative headlines across 8 total articles, including management commentary on complex drug demand and a new payload-linker facility at its Michigan CDMO campus.
Weaknesses
- −Trailing ROE of -4% and net profit margin of -3.67% place the company in active loss-making territory; zero years of ROE above 15% are recorded in the available history.
- −Debt-to-equity of 69.52 is exceptionally high; operating losses alongside this leverage level represent a material balance-sheet risk.
- −The stock is down 18.55% over 12 months and 22.57% from its 52-week high, and remains below the 200-DMA (₹176.22) at the current price of ₹174.87.
- −5-year revenue growth of -0.1% and a consistency score of 28 reflect an absence of durable top-line expansion or earnings quality over the measured period.
Open questions
- ?Does the FY27 complex-drug pipeline — ADC payload-linkers and CDMO specialty molecules — represent a structurally new revenue mix, or is it an extension of the existing contract base that has already produced flat 5-year revenue?
- ?At a D/E of 69.52 with negative profitability, what is the debt maturity profile and near-term refinancing requirement, and how does free cash flow coverage compare to interest obligations?
- ?The forward PE of 40.37 embeds a significant earnings recovery assumption — what revenue growth rate and margin level would be required to justify that multiple relative to the current loss-making baseline?
- ?How does the company's CDMO capacity utilisation trend compare to peers like Dr. Reddy's and Cipla, and does the recent Michigan facility investment indicate improving or deteriorating asset productivity?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| PPLPHARMA | Piramal Pharma Ltd.You're viewing | — | -4.0% | 31 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.7 | +11.8% | 17 |
Technical state
Current price
₹174.87
SMA 50
₹153.42
SMA 200
₹176.22
RSI (14)
61.1 (neutral)
From 52w high
-22.6%
1Y return
-18.6%
3M return
+6.4%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highTrailing ROE of -4% and net profit margin of -3.67% indicate active loss-making operations; the company has zero years of ROE above 15% in the available record and 5-year revenue growth of -0.1%.
- highDebt-to-equity of 69.52 is exceptionally elevated for a pharma manufacturer with negative profitability; the combination of high leverage and operating losses creates material solvency exposure.
- mediumStock is 1.34% below its 200-DMA (₹176.22) and down 18.55% over 12 months and 22.57% from its 52-week high, despite a 6.39% recovery over the past 3 months.
- lowForward PE of 40.37 implies significant earnings recovery relative to currently negative trailing profitability; consistency score of 28 and quality score of 31 (4th of 6 ranked peers) reflect limited historical earnings quality.
Cross-section contradictions
- Forward PE of 40.37 prices in a substantial earnings recovery, yet trailing profitability is negative (ROE -4%, margin -3.67%) with no year of ROE exceeding 15% on record.
- News sentiment is positive (4 of 8 articles positive, 0 negative) and recent 3-month price gain is +6.39%, yet the stock remains 18.55% below its 12-month level and below the 200-DMA.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days